CA2410895A1 - Therapeutic compounds for ovarian cancer - Google Patents

Therapeutic compounds for ovarian cancer Download PDF

Info

Publication number
CA2410895A1
CA2410895A1 CA002410895A CA2410895A CA2410895A1 CA 2410895 A1 CA2410895 A1 CA 2410895A1 CA 002410895 A CA002410895 A CA 002410895A CA 2410895 A CA2410895 A CA 2410895A CA 2410895 A1 CA2410895 A1 CA 2410895A1
Authority
CA
Canada
Prior art keywords
seq
cell
peptide
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002410895A
Other languages
English (en)
French (fr)
Inventor
Charles A. Nicolette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2410895A1 publication Critical patent/CA2410895A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002410895A 2000-05-31 2001-05-30 Therapeutic compounds for ovarian cancer Abandoned CA2410895A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20938800P 2000-05-31 2000-05-31
US60/209,388 2000-05-31
US25700700P 2000-12-20 2000-12-20
US60/257,007 2000-12-20
PCT/US2001/017454 WO2001092306A2 (en) 2000-05-31 2001-05-30 Therapeutic compounds for ovarian cancer

Publications (1)

Publication Number Publication Date
CA2410895A1 true CA2410895A1 (en) 2001-12-06

Family

ID=26904120

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002410895A Abandoned CA2410895A1 (en) 2000-05-31 2001-05-30 Therapeutic compounds for ovarian cancer

Country Status (8)

Country Link
US (2) US6737062B2 (enExample)
EP (1) EP1284997B1 (enExample)
JP (1) JP2004503217A (enExample)
AT (1) ATE292640T1 (enExample)
AU (1) AU2001265188A1 (enExample)
CA (1) CA2410895A1 (enExample)
DE (1) DE60109922D1 (enExample)
WO (1) WO2001092306A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410865A1 (en) * 2000-05-31 2001-12-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
EP1284997B1 (en) 2000-05-31 2005-04-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
EP1359937A4 (en) * 2001-02-14 2004-07-28 Genzyme Corp MODIFIED PEPTIDE LIGANDS
WO2002080845A2 (en) * 2001-04-04 2002-10-17 Genzyme Corporation Novel eps8 compounds for therapy and diagnosis and methods for using same
AU2002232563A1 (en) * 2001-12-05 2003-06-23 Genzyme Corporation Compounds for therapy and diagnosis and methods for using same
WO2003068925A2 (en) * 2002-02-11 2003-08-21 Mosca Joseph D Production of a protein delivery system for in vivo therapeutic treatment
JP2005191530A (ja) * 2003-12-03 2005-07-14 Sumitomo Electric Ind Ltd 発光装置
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20110160130A1 (en) * 2007-02-16 2011-06-30 Connie Erickson-Miller Cancer treatment method
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
KR101530402B1 (ko) * 2007-10-09 2015-06-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (tpora)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5688657A (en) 1988-03-31 1997-11-18 International Bio-Immune Systems, Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
EP0573608A1 (en) 1991-02-07 1993-12-15 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
JPH07101999A (ja) 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするdna塩基配列
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
DE19817946A1 (de) 1998-04-17 1999-10-21 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Uterus-Normalgewebe
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
EP1290217A2 (en) 2000-02-04 2003-03-12 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
EP1284997B1 (en) 2000-05-31 2005-04-06 Genzyme Corporation Therapeutic compounds for ovarian cancer

Also Published As

Publication number Publication date
WO2001092306A2 (en) 2001-12-06
EP1284997B1 (en) 2005-04-06
EP1284997A2 (en) 2003-02-26
US20030175252A1 (en) 2003-09-18
ATE292640T1 (de) 2005-04-15
US20050048068A1 (en) 2005-03-03
JP2004503217A (ja) 2004-02-05
DE60109922D1 (de) 2005-05-12
WO2001092306A3 (en) 2002-08-08
US6737062B2 (en) 2004-05-18
AU2001265188A1 (en) 2001-12-11

Similar Documents

Publication Publication Date Title
US8029796B2 (en) Therapeutic anti-cytomegalovirus compounds
US6737062B2 (en) Immunogenic compositions
AU2001253867A1 (en) Derivatives of breast cancer antigen HER-2 for therapeutical use
US6861408B2 (en) Therapeutic anti-melanoma compounds
US20040138135A1 (en) Therapeutic compounds for ovarian cancer
US20020182218A1 (en) Therapeutic anti-melanoma compounds
US20020169132A1 (en) Therapeutic anti-melanoma compounds
EP1309625B1 (en) Therapeutic compounds for ovarian cancer

Legal Events

Date Code Title Description
FZDE Discontinued